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Thalidomide remains one of the world’s most notorious drugs due to the severe birth defects it induced in children between
1957 and 1962. Yet, to some this drug is a lifesaver, as it now enjoys renaissance in the treatment for a wide range of conditions
including leprosy, multiple myeloma, Behcet’s disease, and some cancers. However, thalidomide has also been linked to causing a
new generation of thalidomide survivors in Brazil, where the drug is used to treat leprosy. Surprisingly how thalidomide causes
birth defects and how it acts in the treatment of clinical conditions are still far from clear. In the past decade great strides in our
understanding of the actions of the drug, as well as molecular targets, have been made. The purpose of this review is to look at
the recent work carried out into understanding how thalidomide causes birth defects, it’s molecular targets and the challenges that
remain to be elucidated. These challenges include identifying clinically relevant but nonteratogenic forms of the drug, and the
mechanisms underlying phocomelia and species specificity.
1. Introduction
1.1. History. Thalidomide was produced and released as a
nonaddictive, nonbarbiturate sedative in 1957 by Chemie-
Grunenthal. Thalidomide was marketed as very safe with
no untoward side effects [1] and quickly became something
of a wonder drug between 1957 and 1961 in the treatment
of a range of conditions, in particular morning sickness.
Thalidomide was marketed in 46 countries, under different
names (e.g. Distaval in the UK and Australia, Isomin in
Japan, Contergan in Germany, and Softenon in Europe) [1–
4]. However soon after the drug’s release in Europe reports
linked thalidomide to causing peripheral neuropathy in adult
patients (which prevented its licensing and general release
in the USA) as well as being behind the occurrence of a
high and sudden increase of rare birth defects [3, 5–8]. The
range and type of birth defects seen were unprecedented with
the most striking and stereotypic feature being phocomelia,
where the handplate remains but the proximal elements are
missing or very short. Children also exhibited amelia in some
cases (no limb) forelimb anomalies, handplate anomalies,
and other damage to ears, eyes, internal organs, genitalia,
and the heart [7, 9–20]. The damage caused by thalidomide
was not mutually exclusive, with the majority of children
exhibiting damage tomultiple organs and tissues [3, 7]. It took
until 1961, when reports and concerns from two independent
clinicians, Lenz in Germany and McBride in Australia,
confirmed that ingestion of thalidomide during pregnancy,
to relieve morning sickness, was the cause of the birth defects
[3, 4, 7, 11, 12, 21]. Thalidomide was finally withdrawn in
November 1961. Thalidomide-damaged children were still
born throughout 1962, but the number of children affected
dramatically declined following thalidomide withdrawal [7,
22]. In total over 10000 children were born with severe
damage worldwide [3, 23].
Thalidomide was not licensed for use in the USA between
1957 and 1961 as Dr Frances Kelsey, a physician working
for the US Food and Drug Administration (FDA) had
concerns about the drug’s safety [5, 24]. Dr. Kelsey was
concerned about the peripheral neuropathy side effect that
had been experienced and reported in some patients in
Europe following thalidomide exposure [3, 5, 25, 26]. Dr.
Kelsey undoubtedly prevented an epidemic of thalidomide-
induced birth defects in the USA and for her efforts was
subsequently given the President’s Award for Distinguished
Federal Civilian Service by President John F. Kennedy in 1962
[4]. Questions still remain about the testing carried out on
Thalidomide before it was marketed in 1957 and whether
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the testing was stringent enough as well as whether the disas-
ter was preventable. Following the thalidomide disaster new
legislation was introduced around the world that changed the
way drugs are tested and their approval for human use, espe-
cially for pregnant women. Indeed Dr Frances Kelsey pub-
lished several papers on improving drug testing and safety,
which form the basis of drug testing carried out today [5, 6].
1.2. Thalidomide Today. In 1965 thalidomide was found to be
very effective in reducing the lesions associated with leprosy
and (ENL), erythema nodosum leprosum, a complication of
leprosy involving a chronic skin and nerve infection caused
by Mycobacterium leprae [27]. This discovery led to thalido-
mide’s actions being studied in detail for clinical purposes.
Reports linked the drug to having anti-inflammatory actions
and being effective as a clinical treatment for Leprosy, ENL,
and other inflammatory disorders. Furthermore studies indi-
cated thalidomide was antiangiogenic and potentially useful
for the treatment of cancers [28, 29]. Today thalidomide is
licensed around the world (including the USA since 1998)
for the treatment of leprosy and multiple myeloma (where
it can prolong patients lives by up to 18 months) [30, 31].
Thalidomide and its analogs are also used to treat a broad
range of other conditions including in the gastrointestinal
system (e.g. Behcet’s disease, Crohn’s disease), rheumatologi-
cal system (e.g. lupus, arthritis, and sarcoidosis), and cancers
(e.g. renal cell cancer, prostate cancer, and Karposi’s sarcoma)
[1, 32, 33]. Recently thalidomide has been shown to be
effective in relieving the clinical symptomsof hereditary hem-
orrhagic telangiectasia (HHT), a bleeding disorder [34] and
idiopathic pulmonary fibrosis [35, 36]. Clearly thalidomide
has some very beneficial clinical uses. However the dark side
of thalidomide still remains. Thalidomide still causes birth
defects today particularly in Brazil—where several children
have been identified with thalidomide embryopathy in the
past few years [37–40].
1.3. Brazil Tragedy. In recent years tragically a newgeneration
of thalidomide survivors have been born and identified in
Brazil [37–40]. This is primarily due to a culture of medi-
cation sharing, less-stringent methods of prescription, mis-
understanding of the drug’s labeling, and pregnant women
taking the drug while suffering from leprosy. Sadly many
children have been identified with thalidomide embryopathy
[39, 40].This Brazilian cohort provides an opportunity to fol-
low these victims from childhood to adulthood usingmodern
diagnostic techniques. Such studies could help determine the
precise range and type of damage at birth as well as late onset
damage. So far, the Brazilian thalidomide survivors appear to
exhibit a similar spectrum of damage as seen in the 1957–61
disaster [39, 40].
2. Thalidomide Embryopathy
(or the Thalidomide Syndrome)
Between 1957 and 1961 thalidomide caused severe birth
defects in at least 10000 children [1, 3]. Although any tissue
of the forming body could be affected by thalidomide some
hallmark features associated with the drug were identified
including damage to limbs, eyes, ears, genitalia, and internal
organs including kidney, heart, and gastrointestinal tract.
Also associated are vertebral column problems and facial
palsy [1, 3, 7, 9, 11–15, 18, 20, 41, 42]. In addition another com-
mon feature was the appearance of a transient haemangioma
on the forehead, which usually disappeared within the first
12–24 months of life [7]. Due to the wide range of conditions
this drug caused the damage is usually referred to collectively
as thalidomide embryopathy or thalidomide syndrome [7,
14, 15]. Infant mortality in babies born with thalidomide
embryopathy is estimated to be as high as 40%, quite likely
due to the serious internal malformations such as heart and
kidney defects [3, 7]. Furthermore many babies with these
serious internal malformations would have been miscarried
or died in utero or soon after birth. Thus, the true number of
babies affected by thalidomide will never be known.
2.1. Thalidomide Acts in a Time-Sensitive Window of Em-
bryonic Development. Thalidomide causes damage to the
embryo in a short timewindow of development (also referred
to as the “critical period”) between 20 and 36 days after
fertilisation, or 34 to 50 days after the last menstrual period
[7, 11, 25]. Exposure to thalidomide from 36 days after
fertilisation has no apparent outward morphological effect
upon the embryo/fetus [7, 14]. In contrast, thalidomide
exposure before the time-sensitive window of development
can inducemiscarriage in humans and rats [9, 43]. Incredibly,
reports indicate just one 50mg tablet of thalidomide during
the time-sensitive window is sufficient to cause birth defects
in 50% of pregnancies, underlining the high teratogenic
potency of thalidomide [7, 14, 15, 25]. Some reports go further
and suggest it would be surprising if any pregnancy went
unharmed following thalidomide exposure during the time
sensitive window [7]. The time-sensitive window was deter-
mined following interviews with mothers of thalidomide-
affected children and their doctors. From these interviews
the dates of intake and the amount of drug exposure were
calculated and an accurate correlation could be made to
the period of exposure and relationship to anomalies in
order to determine the timing of the damage [3, 11, 25]. The
outward morphological birth defects seen in thalidomide
embryopathy are caused and correlate with exposure within
this time period. Exposure to thalidomide in the first few
days of the sensitive period (days 20–24) affected the ears
and eyes, followed by the upper limb (day 24–31) and then
the lower limb (days 27–33), respectively [11, 25]. Effects upon
the nerves, resulting in facial palsies, hearing loss and autism
and epilepsy could be induced from the start of the time
sensitive window, presumably as the brain’s neural wiring is
undergoing great changes at this time. The consequence of
such nerve damage, however, may not be diagnosed until
much later after birth [11, 25, 42]. Thalidomide exposure in
late fetal rat’s indicates that brain damage in areas related to
autism can be a late event [44].
The time-sensitive window coincides with a period of
rapid embryonic development (from 4 weeks onwards) with
lots of cell movements, organogenesis, and many signalling
ISRN Developmental Biology 3
pathways active. Embryogenesis typically lasts until around
weeks 10-11 after conception.Thus,Thalidomide use to relieve
the symptoms of morning sickness (which can occur from
week 4 onwards) coincides with the major developmental
events in the embryo underpinning the thalidomide tragedy
[1, 3].
Exposure to thalidomide after the time-sensitive window
was thought to have no effect upon the embryo. Recent work
has suggested late exposure of rat fetuses to thalidomide
(after the documented time-sensitive window of action in the
late fetal stages) affects angiogenesis in the brain and causes
malformations of the brain in areas linked to epilepsy and
autism, with no obvious limb or other outward morphologi-
cal damage [44]. Epidemiology studies in Sweden have shown
that thalidomide survivors have an increased incidence of
autism when compared to the average population [42, 45].
Together, this work suggests there is unlikely to be a safe time
point in pregnancy for exposure to thalidomide. Exposure
in the time-sensitive window results in a range of outward
morphological damage, with the severity and complexity
depending on timing of exposure. Exposure after the time-
sensitive window could affect growth and maturation of
internal organs/tissues, particularly the brain.
2.2. Limb Defects. Phocomelia is the most striking limb
deformity caused by thalidomide and remains the stereo-
typical image of thalidomide embryopathy. Phocomelia is
a severe shortening of the limbs, where distal elements
(handplate) remains but proximal elements (long bones) are
reduced or missing [7, 14, 15, 46, 47]. Phocomelia itself can
range in severity. The most severe form is where long bones
are missing with just a flipper-like structure consisting pri-
marily of a handplate (though digit number can vary between
affected individuals) articulating directly with the body. Less
severe forms show, for example, a shortening of the long
bones [7, 14, 39, 46]. The majority of thalidomide survivors
exhibit some formof limb deformity for example, phocomelia
to radial dysplasia to triphalangeal thumb [1, 7, 20, 39] Limb
deformities are usually reduction defects and most often
symmetrical [7, 9, 14, 48]. Indeed severe, symmetrical limb
defects remain one of the classical hallmarks for diagnosis
of thalidomide embryopathy. The range and type of limb
deformities following thalidomide exposure are described
in the literature (originating from the 1960s) as exhibiting
a characteristic pattern. The thumb is the first structure to
be affected followed by the radius, humerus, and lastly the
ulna [7, 9, 14, 15, 49]. These descriptions were based on
observations of babies and children with severe forms of
thalidomide embryopathy, usually exhibiting bilateral limb
damage [7, 15, 17].
The lower limb can also exhibit limb deformities. How-
ever abnormalities of the lower limbs are seen less commonly
than those of the upper limbs, with lower limb deformities
on their own being very rare. The reasons for this upper
limb/lower limb sensitivity difference to thalidomide remains
unclear [14, 16, 48].The femur is the bone most often affected
in the lower limb, and like the ulna, in the upper limb, the
fibula is usually the final bone to remain normal [7].
Embryologically, the radius/tibia (preaxial) and ulna/
fibula (postaxial) form in the developing limbs after the
humerus/femur has begun to form. The digits of the
hand/footplate are the last structures to form. Initially the
structures form as cartilage condensations before ossifying
into bone [50–52]. This sequence of limb development
offers some explanation as to why proximal structures are
shortened ormissing but distal structures are present in some
thalidomide survivors; that is, early exposure causes loss of
proximal elements. However how any distal structures then
form or remain is unclear (also see discussion on chondro-
genesis and origins of phocomelia, later in this review).
Why the radius is more sensitive to thalidomide-damage
than the ulna is unclear. The radius is smaller and thinner
than the ulna and so perhaps easier to damage. However,
variations in deficiencies longitudinally have been suggested
to be related to the timing and duration of a teratogenic
insult during early limb development [53, 54]. It has also
been reported that teratogenic insults could induce ulnar
deficiencies earlier in gestation than radial deficiencies [53].
Unilateral limb damage is not considered to be part of
the classical thalidomide embryopathy phenotype. However
there are reports in the literaturementioning cases of thalido-
mide survivors with unilateral limb damage [7, 11, 16, 17, 20,
55]. Unilateral defects, in general, are very rare and how they
come about remains a mystery.
2.3. Shoulder and Hip Joints. Thalidomide survivors also ex-
hibit damage to the shoulder and hip joints where the limbs
articulate with the body and are often weaker than normal.
The acromioclavicular joint of the shoulder is more promi-
nent and sharpened in appearance, when the shoulder is
deformed [14].Thehip jointmay be hypoplastic or completely
absent, as is true for the pubic bone [14]. Damage to the
shoulder and hip joints is a characteristic of thalidomide
embryopathy and in some cases has helped physicians to dif-
ferentiate thalidomide deformities from sporadic or genetic
limb defects. Adult thalidomide survivors have commented
on ongoing joint problems, pain and rotation difficulties and
early-onset osteoarthritis [56, 57].
2.4. Eye and Ear Defects. Damage to the eyes and ears
(internal and external) is also seen in thalidomide survivors.
The eyes and ears form from week 4/5 until around week
8/9, around the same time the limbs are rapidly grow-
ing. Thalidomide can cause small eyes (microphthalmia)
anophthalmos (absence of the eyeball) and poor vision. Eye
defects also include aberrant lacrimation (tear formation),
coloboma and strabismus [7, 14, 17, 20, 25, 45, 58]. Ocular
defects can occur unilaterally although there may still be
poor vision in the unaffected eye [17]. Thalidomide may
also cause abnormalities in eye movement and usually occur
in conjunction with ear defects and weakness of the facial
muscles [7].
Ear defects are usually symmetrical and range from com-
plete absence of the outer ear or pinna (anotia) to part of the
outer ear still remaining (microtia) [7, 59, 60]. Anotia is also
linked to abnormalities of the external auditory meatus and
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such children affected are deaf [60].Thalidomide-induced ear
defects have also been associated with cranial nerve palsies,
resulting in facial palsies [13, 14, 25].
2.5. Facial Damage. Another common feature seen in
thalidomide survivors, again used as a diagnostic hallmark,
is the presence of an enlarged naevus at birth (also known as
a “storkmark”). The naevus is in the centre of the forehead
extending down over the nose and upper lip. This is a
capillary haemangioma and is temporary, usually no longer
visible within 2-3 years of birth [7, 14, 15]. Facial palsy and
facial asymmetry have also been associated with thalidomide
embryopathy [7, 14, 15, 20, 25] and are thought to be due
to weakened facial muscles and facial nerve damage [7, 25].
In addition a range of other effects on facial structures have
been seen in thalidomide survivors including irregular teeth
numbers/spacing, small jaw, cleft palate and cleft lip, and
small noses [7, 14].
2.6. Vertebral Column. Thalidomide survivors can exhibit
spinal problems, including irregular vertebral spacing. Fusion
of vertebrae is also seen in the lower spinal column and
progressive kyphosis which can often require surgical inter-
vention later in life [7, 14]. Thalidomide survivors have also
been reported to exhibit shorter stature than average with the
shortness attributable to short leg bones being independent
of vertebral defects [7, 14, 61]. How these spinal defects occur
following thalidomide exposure is unclear.
2.7. Internal Organ Defects. All of the internal organs can be
affected by thalidomide exposure in utero. Common damage
seen includes malformations of the heart, kidneys, genitals,
and bowel [7]. The precise incidence of such deformities
is unknown as such defects cannot be seen outwardly and
some problems do not always present until later in life.
Defects of the heart were thought to be the cause for many
of the intrauterine and postnatal deaths. Many thalidomide
survivors have heart problems as well as pulmonary stenosis
and patent ductus arteriosus [7, 59].
The urinary tract and kidneys are affected in many
thalidomide survivors, with horseshoe, hypoplastic, and
rotated and ectopic malformations of the kidney seen [7,
14, 15, 17]. Many children also suffered from genital defects,
both internal and external. Absence of the testes, testicular
abnormalities, and hypospadiasis were seen in males, whilst
in femalesmalformations of the uterus and reproductive tract
defects were observed [7, 16, 17, 62]. Thalidomide survivors
exhibited problems in the intestines including anorectal
stenosis, intestinal atresia, pyloric stenosis, and inguinal
hernia [7, 9, 14–17].
2.8. Nerve and CNS Defects. Children with thalidomide
embryopathy did not appear at the time to have impaired
learning disabilities [63, 64]. There is evidence that some
thalidomide-damaged children have facial palsies, cranial
nerve conduction problems, and an increased incidence
of autism and epilepsy in later life [7, 25, 42]. It has been
proposed that thalidomide could affect forming nerve
pathways during, and outside, the time sensitive window
[42, 44, 45] possibly by preventing angiogenesis in the brain
[44] resulting in cell death and loss of tissue and autism.
2.9. Variability of Thalidomide-Induced Damage between
Individuals. An outstanding question, and perhaps ongoing
challenge, is to understand the variability of thalidomide-
induced damage between individuals [1, 7]. Some reports
indicate thalidomide exposure in utero could result in a
50% risk of a birth defect [7, 14, 15]. Given the potency
of the drug how could any pregnancy be unharmed? Why
are some pregnancies apparently unharmed? Aside from
drug exposure in utero outside the time-sensitive window of
action, we know that individuals react differently to drugs
and we know individuals have different metabolic rates.
Birth defects can be multifactorial in origin resulting from
combined genetic and environmental influences [65]. Thus,
these influences (as well as time of exposure) could explain
why some pregnant women are affected by the drug and
others are not, and also explain differences in the severity of
the damage.
2.10. Thalidomide Embryopathy Can, Sometimes, Be Difficult
to Diagnose. Reports have indicated that some thalidomide
survivors may have been misdiagnosed and in fact suffer
from mutations in the SALL4 gene or in the TBX5 gene [66–
68]. SALL4 and TBX5 are both expressed in limbs. Mutation
in SALL4 causes Okihiro syndrome, characterized by limb
reduction deformities. Mutations in TBX5 causes Holt-Oram
syndrome, where heart and limb reduction deficiencies are
apparent. Both Okihiro syndrome and Holt-Oram syndrome
can be difficult to differentiate from thalidomide syndrome as
they can look similar.
In addition another genetic condition that can be con-
fused with thalidomide embryopathy is Roberts syndrome.
Roberts syndrome is also called pseudothalidomide syn-
drome, as it shares striking resemblance to Thalidomide
embryopathy in that the main feature is tetraphocomelia
[69]. Roberts syndrome patients also suffer from facial and
internal organ damage [70]. Roberts syndrome is caused by a
mutation in the ESCO2 gene (Establishment of Sister Chro-
matid Cohesion 2) [71, 72], involved in proper segregation of
chromatids in cell division.This gene has since been found to
be important in control of cell proliferation, cell death and
DNA repair [73, 74]. The advent of genetic screening now
allows better diagnosis of such conditions.
Thalidomide can phenocopy these genetic defects and
further highlights the difficulty in sometimes differentiating
thalidomide embryopathy from other disorders. This also
underlines the difficulties in pinpointing precise diagnostic
parameters of thalidomide embryopathy, given the range of
damage and variability between individuals. Furthermore,
whether these genes may be involved in some of the down-
stream, tissue specific effects of the drug is unclear (see later
section on molecular targets).
2.11. Summary. Thedamage caused by thalidomide is striking
and widespread. The criteria describe above varied between
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individuals, the most severely affected children exhibited
limb malformations, facial, genital and internal organ prob-
lems. These criteria are used to help diagnose thalidomide
embryopathy.The criteria were determined through studying
the most severely affected thalidomide babies/children, usu-
ally those with bilateral limb damage [7]. Damage that may
only have observable effects in later life, such as joint damage
or reduced organ/tissue function could not be properly
determined.Thus, some damage may not have been apparent
at that young age, and may not have been associated as part
of the condition as patients got older. Furthermore, there are
records of children with confirmed thalidomide exposure in
utero with no apparent outward morphological damage [20].
Whether such children have internal organ damage/function
issues is unknown.The precise range of damagemay never be
known. However, the Brazilian thalidomide survivors, many
of whom being children, offer the possibility of studying the
damage caused, its progression and late onset problems.
Today, we are aware of left-right asymmetry differences
in early embryonic formation, asymmetric differences inter-
nally, and genomic variation between individuals which
could influence susceptibility to a drug’s influence [65]. How
thalidomide influences these processes remains unclear but
could shed further light on themolecular and tissue targets of
the drug. Understanding thalidomide and its targets remains
a priority due to its widespread use in clinical treatments
today.
3. Thalidomide Has Side Effects in Adults
Thalidomide is not only toxic to the forming embryo. It
has been known since the original release of thalidomide
that long term use can cause peripheral neuropathy in
adults [5, 75–77]. Peripheral neuropathy is a condition where
nerves are damaged resulting in pain and hypersensitivity,
typically in the extremities [78]. How the drug induces this
condition is unclear; however patients are advised to stop
taking thalidomide if symptoms begin. In patients using
thalidomide to treat leprosy and multiple myeloma, many
suffer from peripheral neuropathy [76, 79].
In addition thalidomide use causes constipation,
dizziness, drowsiness, and skin rashes in some patients.
Recent regulatory advice warns that thalidomide can also
cause blood clots in veins and arteries and has recently also
been linked to inducing secondarymalignancies (http://www
.thalomid.com/; http://www.fda.gov/; http://www.mhra.gov
.uk/Safetyinformation/DrugSafetyUpdate/CON123111; http://
www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/
CON282739).
4. Lenalidomide and Pomalidomide: New
Thalidomide Analogs
New analogs of thalidomide have been developed that are
purported to be safer and more clinically effective than
thalidomide in the treatment of inflammatory disorders.
These analogs, lenalidomide and pomalidomide, are used
to effectively treat multiple myeloma [80]. Pomalidomide
appears to be more effective in treating patients in which
lenalidomide and thalidomide have lost effectiveness [81, 82]
(Figure 1).
However, lenalidomide use has been linked to causing
peripheral neuropathy in patients taking lenalidomide
for multiple myeloma treatment [83, 84]. In addition
lenalidomide, but not pomalidomide, is teratogenic in chick
and zebrafish embryos [85]. Furthermore, both lenalidomide
and pomalidomide are associated with causing teratogenesis
in some mammalian species [86] (also see FDA website:
http://www.accessdata.fda.gov/drugsatfda docs/label/2013/
204026lbl.pdf).Thebasis for these species-specific differences
in action is far from understood (see Species Specificity
section of this review for further discussion).
Clearly, these compounds, including thalidomide, remain
a risk to the unborn child and are only administered under
a strict program which is specifically designed to prevent
thalidomide embryopathy. For example, the System for
Thalidomide Education and Prescribing Safety (STEPS) is a
program that educates clinicians and patients and carries out
regular contraceptive counseling and pregnancy testing [87–
89]. However, presently the other side effects (e.g. peripheral
neuropathy) are sadly part of the risk-benefit decision asso-
ciated with the drug’s health benefits. It remains a primary
goal to ascertain if all such side effects can be prevented or
minimized. Whether new or alternative forms of the drug
can be made retaining the clinically beneficial aspects and
without the side effect aspects is an ongoing challenge.
5. Biochemistry of Thalidomide
Thalidomide is a derivative of glutamic acid, a nonessential
amino acid with important functions in the brain and during
muscle development. Thalidomide exists as an enantiomer
and can switch between its two chiral states in body fluids
and water [29] (Figure 1). It has long been assumed that
one form is the teratogenic causing agent and the other is
the sedative agent. However, the fact they can interchange
indicates just the safe form cannot be given clinically [29, 90,
91]. Thalidomide is metabolically broken down in the liver
by cytochrome P450 (CYP2C19) enzymes and can also break
down hydrolytically in body fluids. Thalidomide has a half-
life of 6–12 hrs [29]. Furthermore there are species differences
in efficiency of breakdown of drug into byproducts; for
example, the rabbit is more effective at breaking down
thalidomide than the rat [92, 93]. This could help explain the
species differences in action of this drug (see later).
5.1. Inflammation. Thalidomide has been shown to inhibit
TNF𝛼 transcription directly through enhanced TNF𝛼mRNA
degradation [94] and COX2 inhibition [95] in monocytes
and macrophage cells. TNF𝛼 regulates and controls the
inflammatory response through inducing cytokines, such
as interleukins (e.g., IL-1 and IL-6), in response to injury
or stimuli. Several autoimmune diseases arise from the
overproduction of unnecessary cytokines in healthy tissue,
leading to potentially debilitating conditions, such as ery-
thema nodosum leprosum (ENL), multiple myeloma (MM),
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Figure 1: Structures of thalidomide and its structural analogs. Thalidomide (a) is enantiomeric and can exist in two chiral states (asterisk
denotes chiral centre). CPS49 (b) is a structural analog based on the antiangiogenic breakdown product of the thalidomide molecule and is
fluorinated to enhance bioactivity and stability [1, 29, 54]. Lenalidomide (c) and pomalidomide (d) are based on the thalidomide structure
and used to treat multiple myeloma.
and Crohn’s disease [96, 97]. The inhibition of TNF-𝛼 by
thalidomide makes this drug excellent in the treatment of
these autoinflammatory diseases.
5.2. Angiogenesis. Thalidomide was first demonstrated to be
antiangiogenic in 1994, through destroying angiogenic vas-
cularization in rat cornea induced by fibroblast growth
factor (FGF) protein [28]. This finding led to the suggestion
that thalidomide may cause teratogenic damage by affecting
blood vessels. Indeed this discovery has made thalidomide
a candidate for treatment of early-onset cancers, to prevent
early cancerous growth/tumors acquiring a vasculature to
grow [29, 90, 91]. Thalidomide is also used to treat multiple
myeloma, which is thought to be due to excessive vascular-
ization of bone marrow tissue and/or due to an overactive
inflammatory response [98], and also treat hereditary hem-
orrhagic telangiectasia (HHT) [34].
Use of CPS49, an antiangiogenic analog of thalidomide,
demonstrated that thalidomide’s antiangiogenic action causes
its teratogenic actions in a time-sensitive manner [54].
6. Angiogenesis and Mechanism of
Thalidomide-Induced Teratogenesis
6.1. Role of Blood Vessels in Embryogenesis. Blood vessels
are essential for normal embryonic formation. Blood vessels
supply oxygen and nutrients to growing tissues and remove
unwanted waste products. Blood vessels form by two main
processes in the embryo: vasculogenesis and angiogenesis
(Figure 2). Vasculogenesis is where the first, primitive blood
vessels form. Endothelial cells migrate toward each other and
coalesce to form vascular tubes. Angiogenesis is where these
primitive vascular tubes are built upon and elaborated to form
the complex networks of vessels throughout all tissues of the
embryo. Endothelial cells proliferate andmigrate to avascular
areas in response to signals such as hypoxia or vascular
endothelial growth factor. Endothelial cells then quiesce and
the vascular tube recruits vascular smoothmuscle cells which
stabilise and strengthen the vessel. In order to undergo later
angiogenesis to further elaborate the network or simply refine
the network, the smooth muscle coating is lost to allow
endothelial cells to migrate and form new vascular tubes
(Figure 2) [99, 100]. As embryonic development proceeds
blood vessels undergo constant rounds of angiogenesis and
stabilisation to accommodate the rapid tissue changes and
growth.
Loss of, or inhibition of, blood vessels during embryoge-
nesis can result in death or severe embryonic development
consequences [99–102]. For example, loss-of-function exper-
iments of genes involved in vascular formation (e.g., VEGF
and Notch) in mouse embryos cause lethality as the vascu-
lature fails to form [99, 100, 103–105]; in zebrafish, Notch
signalling pathwaymutants display vascular disruption in the
forming somites and spine of the embryo resulting in severe
spinal curving of the embryo [106, 107]. Blood vessels are
important for normal embryonic development, and their loss,
unsurprisingly, results in death or birth defect [1, 52, 100, 102].
6.2. Blood Vessels Are Targeted by Thalidomide in Embryonic
Development. Thalidomide has antiangiogenic actionswhich
has been proposed to play a role in thalidomide teratogenesis
[1, 2, 28, 108–110]. Thalidomide can break down into many
byproducts. Many stable, structural analogs of thalidomide
and its breakdown products have been synthesised and can
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Figure 2: Angiogenesis and the action of thalidomide upon
angiogenesis. Primitive vessels form through vasculogenesis where
endothelial cells coalesce to form primitive tubes through which
blood cells pass through. Angiogenesis is the process which elabo-
rates upon these early and newly formed vessels to form vascular
networks throughout tissues and the embryo. Angiogenesis is
essential for formation of the embryo and continues into adult-
hood, for example, wound healing. As vessels form they recruit
vascular smooth muscle which stabilises the vessel into a mature
and quiescent state. Angiogenesis is induced by signals such as
hypoxia inducible factor-1 (HIF1), vascular endothelial growth
factor (VEGF), and transforming growth factor-𝛽 (TGF𝛽). Mature
vessels will shed their vascular smoothmuscle coats and endothelial
cells will proliferate and migrate to the source of the signals and
form new vessels. Thalidomide targets the immature, unstable,
newly formed vessels preventing proliferation and migration of the
endothelial cells. In rapidly growing tissues, e.g. the forming limb,
vessel loss will be devastating, as cell death will be induced and
signalling pathways will be disrupted.
be screened to determine their function, shedding light on
which aspect of thalidomide action, antiangiogenesis, or anti-
inflammation results in teratogenesis [29, 54, 109–111].
CPS49 is one such stable antiangiogenic analog of
Thalidomide (Figure 1). CPS49 is a tetrafluorinated analog
based on the antiangiogenic breakdown product of thalido-
mide, 5󸀠-OH-thalidomide [1, 29]. Fluorination confers stabil-
ity and increased biological activity [1, 29, 110, 111].
Following CPS49 treatment in chick embryos, as limbs
are just forming (E2.5), blood vessels were destroyed within
1 hr of exposure in the embryo and several hours before any
changes in limb signalling gene expression, and cell deathwas
observed (Figure 3). Reduction in limb area was seen within
6 hrs. Truncated limbs were clearly observable by 24 hrs
where increased cell death was observed and loss of FGF and
Sonic hedgehog (Shh) signalling was seen. FGF and Shh are
key signalling molecules in the developing limb controlling
patterning and outgrowth (Figure 3). Thalidomide has also
been reported to cause loss of FGF and Shh signaling in
chick and rabbit embryonic limbs and in zebrafish embryos
[112–114]. In CPS49 treated embryos resulting limbs were
phocomelia-like 7 days after just a single exposure (Figure 3).
Even more interesting is that CPS49 acts in a time-sensitive
window, just likeThalidomide, where early exposure resulted
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Figure 3: Limbdevelopment and thalidomide-induced phocomelia.
(a) Normal limb development. The limb grows out from the
embryonic flank under the control of several signalling regions, the
Zone of Polarising Activity (ZPA) and the Apical Ectodermal Ridge
(AER). These signalling regions release signalling molecules Shh
and Fgf8, respectively, which signal in a feedback loop and control
limb outgrowth and patterning. Ultimately other genes are activated
including Hox genes, which are involved in patterning the fine
detail of the cartilage elements [51, 52]. (b) Model of thalidomide-
induced phocomelia. Thalidomide inhibits blood vessel formation
and migration, resulting in cell death and reduced signalling
between the ZPA and AER. Once thalidomide exposure has ceased
or limb has recovered, AER/ZPA signalling could be reestablished
and remaining cells distalised to produce a phocomelic limb. If
thalidomide exposure was long term, AER/ZPA signalling may be
completely abolished, resulting in Amelia.
in severely truncated limbs and later exposure caused less
severe damage, for example, loss of a digit or digit tips only.
Similarly, in zebrafish embryos blood vessels are stunted and
lost rapidly following CPS49 treatment. Zebrafish embryos
offer the advantage of being able to visualise vessel formation
and migration “live and in vivo” and effects of drug upon
vessel formation andmigration. CPS49 was shown to prevent
endothelial cells from proliferating and migrating to form
new tubes [54]. The action of CPS49 on the endothelial cell
is through preventing cytoskeletal changes and inhibition
of filopodial tip cell formation and migration [54]. It was
further demonstrated, using in vitro rat andmouse aortic ring
culture assays, that blood vessels possessing smooth muscle
coats are protected from the action of the drug, but those
without smooth muscle are destroyed. This indicates that
newly formed and forming blood vessels are susceptible to
thalidomide. Established, quiescent vessels are unharmed. In
the chick embryo the developing limb vasculature does not
possess smooth muscle until quite late in limb development
[54, 115]. This observation correlates with the range of limb
defects seen depending on the timing of exposure. Severe
defects are seen after early exposure, but by the time smooth
muscle has appeared on the limb vasculature, defects are
restricted to digits [54]. In contrast to the limb, at the time
of exposure (E2.5) microvessels in the brain and vessels in
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the neck and body of the embryo possess smooth muscle
coats intimating that these vessels are quiescent and protected
at this time. When the drug was applied to very young
embryos (E1.5), whenmost tissues are being vascularised and
organogenesis is occurring, embryos died [54].
Several nonantiangiogenic analogs and hydrolysis prod-
ucts tested using the same assays were found not to be
teratogenic or harmful to embryos [54]. This work indicated
that the antiangiogenic action of the drug causes a wide range
of limb defects in a time-dependent manner.
A study using a different fluorinated analog of the
thalidomide molecule (fluorothalidomide) in mouse and
rabbit embryo cultures gave a range of damage that dif-
fered from that exhibited following thalidomide exposure
(e.g. no obvious or apparent limb defects) and also broke
down very rapidly [116]. The work suggests fluorination of
compounds changes their activity [116]. Embryo cultures
ideally last around 2 days and as such it can be difficult
to determine the precise range and type of damage caused
by drugs in such embryos (certainly whether limbs exhibit
limb reduction phenotypes ormissing cartilage patterns).The
fluorothalidomide compound appears unstable and could
have broken down before it could cause observable damage
to limbs. Whether there were any effects on limb signalling
pathways (e.g. FGF, Shh, etc.), changes in cell death, or
changes in blood vessel patterning in the early limbs and
embryos is unreported. CPS49 is fluorinated and based on the
structure of the active antiangiogenic breakdown product of
thalidomide and induces a range of damage and molecular
changes in embryonic chick limbs and in vitro assays, which
is consistent with reports from other groups and work using
thalidomide [112–114, 117–120].
Several other studies have also demonstrated that blood
vessels are targeted and destroyed by thalidomide [28, 44,
108, 119, 121]. These include rat and rabbit corneal assays
where blood vessels induced in response to an FGF soaked
bead are destroyed following thalidomide application [28,
108]. In rat fetuses exposed to thalidomide late in gestation,
blood vessels are disrupted which results in brain changes
in areas relating to autism [44]. In chick embryos, nitric
oxide, a molecule required for endothelial cell function, and
that appears to be protective of blood vessels is inhibited
by thalidomide causing vessel loss. Overexpression of nitric
oxide rescues and/or prevents thalidomide-induced damage
[119, 121, 122]. In zebrafish embryos thalidomide causes blood
vessel defects [54, 123] through VEGF receptor depletion
[123].Thalidomide has also been shown to stabilise hereditary
hemorrhagic telangiectasia (HHT) in adult patients where
“leaky” vessels stabilise through recruitment of smooth mus-
cle and inhibition of angiogenesis [34].
Furthermore, it is known that other antiangiogenic drugs
are teratogenic, for example, sodium valproate [102, 124].
Moreover, loss of blood vessels in early development is usually
lethal or causes serious deformity/damage [1, 52, 54, 100, 102,
115].
Many important molecules involved in embryonic vas-
cular development have been reported to exhibit changed
expression patterns following thalidomide exposure, for
example, actin and tubulin, integrins, vascular endothelial
growth factor, PDGF𝛽, nitric oxide, ceramide, angiopoietins,
and reactive oxygen species [28, 34, 114, 121–123, 125–127].
Altogether there is a large body of evidence indicating a
role for blood vessel damage leading to thalidomide embry-
opathy (also see later Nitric Oxide sections).
6.3. Other Mechanisms of Thalidomide-Induced Teratogenesis.
Many models, theories, and hypotheses have previously been
presented to try to explain thalidomide-induced embryopa-
thy since the 1957–61 disaster. More than 30 models/theories
have been described and include actions on nerves, chondro-
genesis, cell death, and DNA.Many signaling molecules have
been linked to causing thalidomide embryopathy, including
FGF’s and IGFs [1, 2, 8, 128, 129].Themajority of thesemodels
do not appear to be able to account for all the damage caused
in the embryo by the drug nor the time sensitive nature of the
drug, and the majority focus primarily on the limb damage.
Some of the popular models are described further below.
However these models do not need to be mutually exclusive
and if put together to produce a framework, in my opinion,
can explain the primary and secondary consequences of
thalidomide embryopathy (see Figure 4).
6.3.1. Nerve Toxicity. McCredie andMcBride (1973) [130, 131]
proposed that thalidomide could affect neural crestmigration
and nerve innervation of tissues resulting in limb outgrowth
and other tissue formation failure. However, studies looking
at nerve functions in the developing chick and mouse limb
indicate that following a loss of nerves, limbs form a normal
pattern, although limbs and limb cartilage elements can
be shorter in length [132–136]. Furthermore limbs are not
innervated until relatively late in limb development, well after
limb initiation and outgrowth [134, 137]. How embryonic
nerve damage can explain the range of damage and the
time sensitive nature of the drug is unclear. It is more likely
that nerve damage is secondary to the initial insult of tissue
loss through loss of vessels, causing misinnervation and
exacerbating the damage.
6.3.2. Cell Death and Reactive Oxygen Species (ROS) Induc-
tion. Thalidomide induces formation of reactive oxygen
species (ROS) and also cell death in limb tissue [114, 118, 125,
138, 139] and could explain the loss of skeletal elements in the
limb as well as other damage to tissues in the body. Induction
of oxidative stress in embryonic tissue is required to cause
thalidomide embryopathy through cell death induction [114,
118, 125, 138, 140]. ROS induction is linked to causing terato-
genesis by other drugs, for example, ethanol and phenytoin
[65, 140]. However how thalidomide induces the cell death
and ROS in specific tissues and in a time sensitive manner
is unclear. Interestingly, cell death induction has also been
observed in the forming limb following application of CPS49,
an antiangiogenic analog of thalidomide, suggesting the
inhibition of blood vessels could be a trigger or involved in
induction of ROS and cell death [1, 54].
6.3.3. Chrondrogenesis. Chrondrogenesis is the process by
which the cartilage condensations of the skeletal elements
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Figure 4: Framework of thalidomide teratogenicity. Thalidomide is
broken down into active byproducts. The antiangiogenic byproduct
inhibits new blood vessel formation in forming tissues and organs
(but not mature, vascular smooth muscle coated vessels). The
endothelial cells are prevented from proliferating and migrating
due to actin cytoskeleton changes. Cell death and localised reactive
oxygen species (ROS) are induced and gene signalling pathways are
affected resulting in further cell death. In rapidly forming tissues
and organs, such as a limb, this is devastating causing tissue loss,
for example, of chondrogenic precursor cells, and deformity. The
damaged and malformed tissues would then fail to recruit or result
in failed secondary cell population migrations, such as nerves and
muscles. Suchmigrating cell types would bemispositioned resulting
in a worsening of the defect. The framework could also be applied
to tissues and organs that have formed and been patterned before
thalidomide exposure. In this case new vessel formation would be
inhibited and localised cell death/gene changes would occur as the
tissue tries to mature and grow resulting in reduced size and/or
reduced physiological function.
form from mesenchyme, and which later differentiate into
bone. Thalidomide and its antiangiogenic analog CPS49
induce increased cell death in the early developing limb,when
proximal limb element precursors are likely forming, causing
limb element reduction or loss [54, 114].
It will be interesting to determine if other chondrogenic
condensations in the embryo are similarly affected by thalido-
mide, for example, the vertebral column.
Phocomelia. The stereotypic limb anomaly associated with
thalidomide embryopathy is phocomelia, where proximal
limb elements are missing or reduced, but distal elements
remain. How does phocomelia come about? Phocomelia can
be induced experimentally by X-irradiating the early chick
limb bud, resulting in loss of proximal skeletal elements
[141, 142], and also through physical removal of proximal
and medial limb mesenchyme [143–145]. Reduction of FGF
signaling in the forming mouse limb can also cause pho-
comelia through loss of proximal elements by increased cell
death [146]. We have previously proposed that phocomelia
could arise, following thalidomide exposure in early limb
development, by loss of blood vessels, inducing cell death and
loss of or reduction of distal limb signalling, which recovers
to distalise remaining tissues (Figure 3) [1, 54]. We know
thalidomide and CPS49 induce increased cell death followed
by loss of FGF signaling from the apical ridge in treated
limbs soon after drug exposure [54, 112–114]. Could apical
ridge signaling recover to signal to anddistalise the remaining
mesenchymal cells? In chick limbs where proximal and
medial tissues have been experimentally removed to induce
phocomelia, an upregulation of FGF signaling was observed
24 hrs after tissue removal [145]. In thalidomide exposed
rabbit embryos, FGF signalling was reduced in limbs buds,
but recovered a fewdays later, and phocomelic limbs can form
[112].This suggests some distal limb signalling recovery could
be a key to understanding thalidomide-induced phocomelia.
Alternatively, or in addition, following thalidomide exposure
could the early loss of blood vessels and subsequent induced
cell death interfere with or prevent cartilage condensa-
tion/ossification resulting in shortened/missing elements?
And/Or could other distally expressed genes be activated
prematurely at the expense of more proximal genes?
6.3.4. DNA Interaction and Mutagenesis. Based on the struc-
ture of thalidomide, it has been suggested that thalidomide
could intercalate into and/or interferewithDNA function, for
example, gene activation [8, 128, 129, 147, 148]. Thalidomide
has also been proposed to be able to form dimers which could
interact transiently with DNA [147]. It remains unclear how
such intercalation/interference events would account for the
range and severity of damage induced by thalidomide.
Thalidomide is not mutagenic nor are defects hereditary
[66–68, 149, 150]. Reports suggesting thalidomide may be a
mutagen followed the birth of a child exhibiting thalidomide-
like damage to a thalidomide-damaged parent caused obvi-
ous concern [151]. However several detailed and controlled
studies have concluded that thalidomide has no mutagenic
activity [66, 149, 150]. As discussed earlier, thalidomide
can phenocopy some human syndromes, for example, Holt-
Oram syndrome, and it can be difficult to differentiate
between these conditions, without genetic testing [67, 68].
Furthermore, an epidemiological study in Sweden followed
offspring from thalidomide survivors and found no evidence
of transmission of thalidomide-damage in the offspring [150].
7. Molecular Targets of Thalidomide
7.1. Cereblon. Cereblon is a candidate gene for mental retar-
dation and has been identified as a binding target of thalido-
mide leading to limb teratogenesis [113]. Cereblon has also
been demonstrated to be required by thalidomide, lenalido-
mide, and pomalidomide to exert their anti-inflammatory
actions [152–154]. Cereblon clearly has multiple important
functions in the embryo and body involved in the inflam-
matory response, mental abilities, teratogenesis, and also
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metabolism [155], but its full role in development remains to
be characterised.
Cereblon is part of a ubiquitination complex involved in
regulating the removal of proteins in the cell and tissues of the
embryo/body. Thalidomide is proposed to bind to Cereblon
in the forming limb which then causes a misregulation
of signalling in the cells and limb bud due to the loss
of ubiquitination activity and which results in thalidomide
induced limb defects [113]. Overexpression in chick limbs
and zebrafish embryos of a mutant form of Cereblon that
cannot bind thalidomide rescues the teratogenic effects of
the drug [113]. Several studies in chick, rabbit, and zebrafish
fins show that thalidomide reduces FGF signalling from
the apical ridge [54, 112–114]. This led to the proposal that
following thalidomide binding to Cereblon perhaps FGF
signalling misregulation may occur in the limb [113, 156].
However the use of an antiangiogenic analog of thalidomide,
CPS49, demonstrated reduction and loss of FGF signalling
from the limb apical ridge is secondary to the loss of blood
vessels and the induction of mesenchymal cell death [54].
In addition, the embryonic expression pattern of Cere-
blon is unclear. Presently, reports suggest Cereblon may be
ubiquitously expressed in human and mouse tissues [113].
How Cereblon binding to thalidomide can lead to the time
sensitive and tissue specific defects associated with thalido-
mide embryopathy remains unclear. Furthermore, a recent
study investigating Cereblon function generated a loss-of-
function mutant mouse line (where the gene was inactivated
throughout the mouse). The study reports that Cereblon
is a negative modulator of AMP-activated protein kinase
(AMPK), leading to protection against enhanced weight gain
in high fat diets [155]. Strikingly, the mice have no apparent
change in limb morphology or facial morphology, in fact the
mice appear physically and morphologically normal, though
whether the mice suffered from mental disabilities or late
onset morphological problems was not reported [155].
Further studies are required to determine Cereblon’s role
in teratogenesis.
7.2. Actin Cytoskeleton. Thalidomide, lenalidomide, and
CPS49 have each been shown to affect the actin cytoskeleton
and cell migratory ability of endothelial cells [54, 85, 121,
157, 158]. Actin is upregulated and tubulin is downregulated,
indicating cells can not proliferate nor migrate. Indeed
filopodial extensions from migrating endothelial cells are
inhibited, following CPS49 exposure, preventing vascular
tube formation [54]. Could amolecular target of thalidomide
in endothelial cells be the actin cytoskeleton? A GeneChip
Array screen of monkey fetuses exposed to thalidomide
indicated a high number of vascular and cytoskeletal marker
changes [159]. Whether these are primary or secondary
targets remains to be determined.
7.3. Nitric Oxide. Nitric oxide has a role in blood vessel pro-
tection and has been shown to be able to rescue thalidomide-
induced damage [119, 122]. A recent study looking at human
thalidomide survivors indicated survivors have a higher
frequency of polymorphisms associated with reduced Nitric
oxide expression, suggesting individualswith such a genotype
could be more susceptible to thalidomide damage [160].
perhaps due to reduced protection of blood vessels.
7.4. Molecular Screens. Recently proteomic and transcrip-
tomic screens of thalidomide treated human embryonic stem
cells and GeneChip Array and Bioinformatics screens of
thalidomide treated cynomolgusmonkey fetuses have looked
for molecular targets of thalidomide [159, 161]. In the human
cell lines changes in limb, heart, nerve and embryonic sig-
naling molecules were uncovered [161]. Strikingly more than
2000 gene profiles were changed in the monkey tissue with
the majority being related to actin cytoskeleton, the vascula-
ture and inflammatory response [159]. Together these screens
indicate there are many potential targets of thalidomide.
Altogether and as described earlier in this Review, many
genes and molecular pathways have already been linked to,
or even shown to have changed gene expression patterns
following thalidomide exposure. The challenge now is to
determine the precise order and number of the molecular
targets and downstream signaling events and how they
lead to teratogenesis. Determining the molecular targets of
thalidomide that result in teratogenesis could help develop
forms of the drug that retain clinical relevance without the
teratogenic side-effect.
8. Framework of Thalidomide Teratogenicity
Amodel underlying the mechanism of thalidomide-induced
teratogenesis needs to explain the time-sensitive action of the
drug on all tissues, including, limbs; ears; eyes; facial, internal
organ; and genitalia.
All of the models proposed to explain thalidomide
embryopathy are not necessarily mutually exclusive and to
some extent each of these models can explain an aspect of
Thalidomide embryopathy. Effects upon the vasculature have
been demonstrated to cause embryonic defect [34, 54, 119,
121, 123] and molecules involved in vascular development are
changed following thalidomide exposure [102, 119, 121, 123,
159–161]. Furthermore, the antiangiogenic analog of thalido-
mide, CPS49, acts in a time sensitive manner in the chick
embryo [54]. The action of thalidomide upon blood vessels,
together with evidence that birth defects can be caused by
damaging blood vessels either through drug exposure, for
example, sodium valproate [124] or by genetic ablation, for
example, in zebrafish [106], suggests the triggering event lead-
ing to thalidomide embryopathy could well be blood vessels.
Thus, at this point, angiogenesis could be the triggering event
and by putting together the other models we can produce a
framework fromexposure to defect and further consequences
(Figure 4). What remains unclear is the molecular target(s).
Thalidomide breaks down into a range of byproducts
through metabolism and hydrolysis [29]; the antiangiogenic
byproduct causes teratogenesis [1, 2, 54]. Blood vessels are
essential for the development of tissues and organs [100].
Exposure to thalidomide during periods of rapid angio-
genesis and tissue formation results in vascular formation
failure, induction of cell death and ROS in cells requiring
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oxygen and nutrients, and gene expression changes. Such
exposure during early limb formation, orwhen tissues/organs
are rapidly forming, is devastating. If the antiangiogenic
insult occurs earlier in development, when all vessels are
angiogenic and all the major tissues and organs are forming,
this could result in cell death in the tissue concerned and
misexpression of signalling pathways. The resulting loss or
misdevelopment of tissue may well be lethal or then result
in the failure of the correct recruitment and differentiation of
other cell types including nerves, neural crest, chondrocytes
muscle (particularly if the tissue was severely damaged,
resulting nerve innervationwould be severely compromised).
This would also impact internal organ function as well as
nervous system function, exacerbating the defect in the
already damaged tissue (Figure 4).
The Framework would predict that late fetal exposure
to thalidomide could damage newly formed/forming blood
vessels in the internal organs/tissues as they are growing and
maturing preventing proper maturation/growth of the organ
or proper function. Such dysfunctionmay not be detected for
some time after birth depending on the amount of damage
[1, 2]. Interestingly, a study in rats following late fetal exposure
to thalidomide found that the fetal rats had neurological
damage in areas of the brain associated with autism, and this
appeared due to a loss of blood vessels [44].
9. Species Specificity
It is well known that thalidomide exhibits species-specific
differences in its teratogenic actions [1, 3, 8, 129].Many animal
organisms have been used to study thalidomide’s actions,
including chicks, rabbits, zebrafish, marine fish, armadillos,
marsupials, hydra, and nonhuman primates [1, 2, 44, 54,
121, 123, 159, 162–165]. One of the surprising aspects of
thalidomide is that rodent embryos are less sensitive to
thalidomide with varying results of activity as well as being
mouse strain specific [166] and as such customarily are
not seen as a primary tool to study thalidomide induced
teratogenesis [165, 167–174]. In fact the thalidomide disaster
of 1957–61 indicated, for the first time, that species differences
exist in the reaction to drugs.
Rabbits and nonhuman primates, though useful, have
small litter sizes (and rabbits also resorb malformed fetuses
in utero making it difficult sometimes to determine the full
range of damage, etc.) requiring large numbers of animals
to be used. Furthermore, the action of the drug (as well as
the timing and range of damage) cannot be followed “in
vivo” in the living embryo of rabbits, rodents, marsupials,
and nonhuman primates. Embryo cultures of rabbit embryos
indicate thalidomide and it’s breakdown products teratogenic
actions can be studied in vitro [175]. In addition, despite
rodents being less sensitive to thalidomide, mouse embryo
cultures following thalidomide exposure have been carried
out and typically such embryos survive up to 2 days and
exhibit thalidomide-like damage [116, 166]. Although these
embryo culture techniques are very useful and informative,
it can be difficult to determine the precise range of damage
to the limbs and other tissues as the cultures do not develop
consistently further than around 2 days. Efforts to improve
the length of time mouse and rabbit embryos can be cultured
in vitro would be a major advance. Specifically allowing the
genetic tractability of the mouse to be used to understand
molecular targets of thalidomide in more detail. Chick and
zebrafish embryos offer goodmodels to study drug action and
toxicity on limb and embryonic development and to follow
the effects “live” and have been widely used [54, 85, 113, 114,
117, 121, 123, 124, 176, 177].
Species-specific differences in teratogenic action are also
apparent for lenalidomide and pomalidomide. Lenalidomide
is nonteratogenic in rabbits [178] but is in chick and zebrafish
embryos [85] and in monkeys. In contrast pomalidomide is
not teratogenic in chick and zebrafish embryos [85] yet is
teratogenic in rats and rabbits [86] (http://www.accessdata
.fda.gov/drugsatfda docs/label/2013/204026lbl.pdf).
What are the reasons for these species differences in
activity? Many theories have been proposed, including
metabolism differences between the species. Thalidomide
has more antiangiogenic activity following incubation with
human and rabbit liver microsomes than rat microsomes
[92, 93]. Whether the teratogenic breakdown products of
thalidomide are made in the mouse embryo or are present
long enough is also unclear as clearance of the drug is
extremely rapid in mice compared with humans [179, 180].
To add further complexity to the issue, thalidomide treated
with rat liver homogenate can cause embryotoxicity in chick
embryos suggesting that even though rat liver is not as
effective as human and rabbit in thalidomide metabolism,
the enzymes are present [181]. Metabolic clearance rates may
differ between species, meaning teratogenic forms of the drug
may not be present for long. Placental transport differences
could also exist between species. It remains unclear how the
drugs gain access to cells, whether through a receptor or
transport channel.
9.1. Glutathione and ROS Differences. A study reported that
mouse embryonic fibroblasts have high levels of glutathione
which inhibit superoxide formation and thus prevent ROS
formation and prevent cell death induction [182]. In contrast
human cell lines have low levels of glutathione and are
suggested to be more able to produce ROS following thalido-
mide exposure [120, 182]. Likewise mice embryos suffer from
thalidomide-induced embryopathies when glutathione is
depleted [140]. As discussed earlier, production of ROS leads
to cell death and embryopathy but how the time sensitive
and tissue specific actions come about requires further study.
As depleting glutathione makes mouse embryos sensitive to
thalidomide, perhaps this is one method to potentially open
the mouse embryo up for thalidomide teratogenesis studies
[140, 182].
Understanding the basis of species specificity may help
understand how to make improved or alternative drugs that
cannot cause teratogenesis or perhapsmake forms of the drug
that cant break down into teratogenic byproducts.
9.2. Screening for Safer and Nonteratogenic Forms of Thalido-
mide. Clearly thalidomide and its licensed sister compounds,
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lenalidomide and pomalidomide, are clinically useful, par-
ticularly for treatment of multiple myeloma. However, they
retain nasty and unwanted side-effects. We still do not
fully understand how these side effects are caused or come
about. Moreover, administering a compound that exerts anti-
inflammatory and antiangiogenic effects for an inflammatory
condition is not desirable. What would be therapeutically
more effective would be to retain the clinically relevant
aspects of the drug and lose the bad aspects and also to have
more targeted and tissue specific versions. Can this be done?
The antiangiogenic action of thalidomide has been
demonstrated to cause teratogenesis in chick and zebrafish
embryos [1, 54]. It is also known that lenalidomide and
pomalidomide also have antiangiogenic properties in rodent
assays and myeloma cell lines [157, 158, 183, 184]. Lenalido-
mide is also antiangiogenic (and teratogenic) in chicken
and zebrafish embryos, whereas pomalidomide is not [85].
Precisely what the molecular targets of these compounds are
remains unclear.The nature of the species-specific differences
in action is also unclear. However this indicates that the
antiangiogenic action of these compounds likely underlies
their teratogenic activities. Producing versions of the drug
or alternative drugs without the antiangiogenic actions but
retaining anti-inflammatory actions could, ultimately, follow-
ing testing in higher species and clinical trials, produce a
compound retaining clinical benefit for treatment of inflam-
matory disorders with reduced side effect.
Indeed, some non-antiangiogenic analogs and hydrolytic
break down products of thalidomide have been shown to
be nonteratogenic in chicken embryos [54]. This indicates
the possibility that screening other structural analogs of
thalidomide could lead to identifying compounds with spe-
cific actions with reduced or lessened side effects. Further
work is required to elucidate analogs/derivatives that are
purely anti-inflammatory or purely antiangiogenic. Such
analogs/derivatives could initially be screened in embry-
onic systems as well as in vitro assays to investigate their
effects/actions upon angiogenesis, inflammation, terato-
genicity, and nerve function. Identification of such com-
pounds could mean, after further testing and screening
in mammalian and human model assays, potentially more
targeted compounds to treat inflammatory disorders without
the spectre of birth defect or peripheral neuropathy but also
to treat cancers without the side effect of dampening down
the inflammatory system.
10. Conclusion
How thalidomide causes birth defects has puzzled scientists
and clinicians alike since the first cases of thalidomide embry-
opathy were described between 1958 and 1961. Thalidomide
remains an enigma in many respects. Thalidomide caused
the biggest medical disaster of all time, founded the field of
modern toxicology, and changed forever the ways drugs are
tested. Yet, we still do not fully understand how this drug
caused the range and severity of birth defects, nor do we
understand the drug’s species specific differences in action.
Thalidomide has important functions in the inflammatory
and vascular tissues and it is also unclear how precisely the
drug acts in these tissues.
In the past decade great progress has been made in eluci-
dating themechanismsunderlying thalidomide embryopathy
and its targets and making safer forms of the drug. Thalido-
mide and its analogs, lenalidomide and pomalidomide, are
used to treat multiple myeloma and leprosy. Thalidomide
is also used to treat Crohn’s disease, Behcet’s disease, HIV,
and cancers. But they still have serious side effects, such as
peripheral neuropathy. And tragically thalidomide embry-
opathy still occurs, particularly in Brazil. Understanding
how thalidomide causes birth defect remains important to
determine as does how it treats the conditions it is successful
in. Ultimately this information will help to make safer forms
of the drug targeted for specific conditions without the side
effects.
Thalidomide’s action on the forming vasculature causes
limb defects and likely damages other tissues through
destroying vessels as tissues are forming, growing and requir-
ing a vasculature. By uniting the many models suggested
for thalidomide embryopathy, a framework of thalidomide
teratogenesis can be produced which acts as a template for
effects on all the other tissues affected by thalidomide.
Yet significant challenges remain, specifically under-
standing the molecular target/s and/or sequence of events
resulting in thalidomide embryopathy and determining the
basis of species specificity differences in the action of drug.
Furthermore, given the actions of the drug on different path-
ways, understanding how to modulate these for the benefit of
the patient to make safer and tissue specific/targeted versions
of the drug remains an important goal.
Finally, how does thalidomide induce phocomelia (loss of
proximal elements)? Does it arise through a recovery of apical
ridge signalling, after loss of limb mesenchyme, distalising
the remaining mesenchyme? Or could the early loss of
blood vessels and cell death induction directly interfere with
cartilage condensation/ossification processes resulting in
shortened/missing proximal elements. Or could phocomelia
arise due to changes in limb patterning signallingwhere distal
markers come on earlier than normal in the damaged limb?
Understanding the mechanisms underlying phocomelia will
also help further understanding on normal mechanisms
controlling proximodistal patterning of the limb bud.
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